Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Characterisation of the megakaryocyte proteome in patients with Philadelphia negative myeloproliferative neoplasms

View Full Paper
Ask AI
Bookmark
Share

Authors

CBCavan BennettLDLaura F. Dagley

Discussion

Loading...

Member takes

Overview

Comprehensive analysis reveals disease-specific megakaryocyte proteome alterations in myeloproliferative neoplasms, highlighting potential biomarkers.

Key Points

  • Differentially expressed proteins in megakaryocytes confirmed distinct disease profiles among myeloproliferative neoplasms.
  • Mass spectrometry identified 948, 57, and 83 differentially expressed proteins in primary myelofibrosis, polycythemia vera, and essential thrombocythemia respectively.
  • Pathway analysis revealed upregulation of complement cascade and interferon signaling pathways in primary myelofibrosis megakaryocytes.
  • Findings may facilitate the identification of potential biomarkers and therapeutic targets for myeloproliferative neoplasms.

Cite This Study

Bennett et al. (2025) studied this question.

synapsesocial.com/papers/69362f7f4fa91c937236e5a0https://doi.org/10.1182/blood-2025-5539
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1A Proteomics-Driven Machine Learning Tool for Distinguishing ET from pre-PMF2025
  2. 2Proteomic analysis identifying biomarkers in the progression from essential thrombocythemia to post-essential thrombocythemia myelofibrosis: A retrospective cohort study2025
  3. 3Single cell transcriptional profiling reveals distinct subsets of human megakaryocytes in myelofibrosis2025
  4. 4Peripheral blood plasma proteomics reveals dysregulated cholesterol transport and complement pathways in myeloproliferative neoplasms2025
  5. 5Peripheral blood-based single-cell and genomic profiling of hematopoietic stem and progenitor cells enables accurate diagnosis and risk stratification in myeloproliferative neoplasms2025